** Medical device maker Boston Scientific BSX.N shares up 4.6% to $55.08 on Monday as buyback program fast-tracked

** Co early Monday said entered into accelerated share repurchase (ASR) agreement with JPMorgan Chase for $2 bln of its stock, as part of previously announced $5 bln share repurchase authorization

** Under the ASR terms, BSX to receive stock with aggregate value of 80% of the repurchase price based on Friday's close, and represents approx 30.4 mln shares

** Final settlement of agreement expected to be completed by June 30, 2026, and ASR expected to be $0.02 accretive to its FY26 adj EPS guidance announced last month

** In other co news, BSX said it made $1.5 bln investment in privately held MiRus in a deal that gives BSX an exclusive option to acquire the MiRus TAVR (transcatheter aortic valve replacement) system

** On Apr 22, BSX slashed its annual adj EPS forecast and cut its full-year organic rev growth forecast to 6.5%-8%

** Despite the gain, BSX stock down ~42% YTD vs ~6% decline in S&P 500 Healthcare sector .SPXHC

** Of 37 analysts, 32 rate the stock "strong buy" or "buy", 5 "hold"; median PT $85, per LSEG data